Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2024 08:00 ET | Source: Insignis Therapeutics, Inc.

Insignis Therapeutics Receives Positive FDA Feedback on IN-001 Clinical Program for Needle-Free Anaphylaxis Treatment

Insignis Therapeutics advances IN-001, a needle-free anaphylaxis treatment, following FDA’s positive feedback and Fast Track designation.